Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Amgen and Novartis inaugurated a much-anticipated new class of migraine drugs Wednesday with FDA approval for Aimovig, an injectable med laden with blockbuster hopes. But Aimovig has several more hurdles to clear before it can reach those lofty goals.